

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3338545
<b>Application Number:</b>	10541195
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	7746
<b>Title of Invention:</b>	Alpha-aminoamide derivatives useful as antimigraine agents
<b>First Named Inventor/Applicant Name:</b>	Patricia Salvati
<b>Customer Number:</b>	37509
<b>Filer:</b>	Daniel M. Becker/Paula Hurley
<b>Filer Authorized By:</b>	Daniel M. Becker
<b>Attorney Docket Number:</b>	373987-004US (396982)
<b>Receipt Date:</b>	21-MAY-2008
<b>Filing Date:</b>	30-JUN-2005
<b>Time Stamp:</b>	16:36:49
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part/.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	efsidstrans.pdf	32680 7bab7dbbe0e033ae8440d5406f153798a8c e417bb63	no	1

### Warnings:

Information:
--------------

2	NPL Documents	NakamuraEffect.pdf	412879 546472b0e4cc0d99782d367022d15e 7819e07	no	5
---	---------------	--------------------	---	----	---

**Warnings:**
**Information:**

3	NPL Documents	Noticeofdismissal.pdf	40267 0fe153bd9d7d8b3c47a53e964d5a3aef d9c08110	no	2
---	---------------	-----------------------	---	----	---

**Warnings:**
**Information:**

4	NPL Documents	BrazilianOAWrittenOpinionEnglishtranslation.pdf	83738 997707255ca0233d1a516d54d5uc5 bc0566731	no	3
---	---------------	---	---	----	---

**Warnings:**
**Information:**

5	NPL Documents	Peiti.pdf	244939 81a1aae569d3d45ad2719b507fbcd 28fb9c4	no	11
---	---------------	-----------	--	----	----

**Warnings:**
**Information:**

6	NPL Documents	PeverelloSynthesis.pdf	1193502 4765855ca4ec4330a9b5a9a9c1194 a03366d4	no	12
---	---------------	------------------------	--	----	----

**Warnings:**
**Information:**

7	NPL Documents	Pevarellostereoslectivity.pdf	230347 e65569a32d7ad19adbe1b0d10c10e 12179e91	no	3
---	---------------	-------------------------------	---	----	---

**Warnings:**
**Information:**

8	NPL Documents	PuigFormalin.pdf	1007620 1374244caee683110b97eda0dd9c16c2 064236551	no	11
---	---------------	------------------	--	----	----

**Warnings:**
**Information:**

9	NPL Documents	Reuter.pdf	314461 e7a1c508a7913432048d6e3d30576 629fe5916	no	10
---	---------------	------------	--	----	----

**Warnings:**
**Information:**

10	NPL Documents	Salvati.pdf	142959 f95302d1ca81689c329b6c344962cf2 8329056	no	4
----	---------------	-------------	--	----	---

**Warnings:**
**Information:**

11	NPL Documents	SaxenaPharmacology.pdf	718828 f93b00da1253a4c734ddfa85bf7eb002 87d15d	no	8
----	---------------	------------------------	--	----	---

**Warnings:**
**Information:**

12	NPL Documents	ShibataModified.pdf	485455 165a0c675a949366475a2e2ef8fc2a488 94c91e0c	no	6
----	---------------	---------------------	---	----	---

**Warnings:**
**Information:**

13	NPL Documents	SteinerLamotrigine.pdf	66092 de052ab220a05931a6813d9043a0a097d 91c1944d	no	7
----	---------------	------------------------	--	----	---

**Warnings:**
**Information:**

14	NPL Documents	Stysonic.pdf	1101188 870622edcaedf5eae591bc79009b12 37927166	no	10
----	---------------	--------------	---	----	----

**Warnings:**
**Information:**

15	NPL Documents	SupplementalVieth.pdf	1660559 48564ddbb11cfa5ca87d7efaf5d48472 b9d00c5	no	44
----	---------------	-----------------------	--	----	----

**Warnings:**
**Information:**

16	NPL Documents	TanelianNeuropathic.pdf	250507 f95a4cb7b47aae7071655daa4009e13cb eaa4b055	no	3
----	---------------	-------------------------	---	----	---

**Warnings:**
**Information:**

17	NPL Documents	TanelianSodium.pdf	587601 3349520x310442de8336998c34843d2 fb81b716	no	6
----	---------------	--------------------	---	----	---

**Warnings:**
**Information:**

18	NPL Documents	TaylorNaChannels.pdf	638799 6b46dd511d75b621b64e89409511da e1df9322	no	8
----	---------------	----------------------	--	----	---

**Warnings:**
**Information:**

19	NPL Documents	TjolsenFormalin.pdf	1273476 b420c3bd06e0d4ff4883a100293a65d02 99f4513	no	13
----	---------------	---------------------	---	----	----

**Warnings:**
**Information:**

20	NPL Documents	Vaghi.pdf	128871 6649fdcc2bae8391ef5d99d57db4b623d 4b73c65	no	5
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Varasisynthesisabstract.pdf	58313 f8cddfb4463bbaa397a0a9575594e3c0 6873b1	no	2
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Varasi2.pdf	111049 f6a43e9d502da83393baa50b7328875 d4d1c8	no	2
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Vieth_characteristicphysicalproperties.pdf	790584 3223965c9e7aa004ef081be85092baa fb62274	no	9
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	WebberObservations.pdf	201561 2b7176650289e7236332a7fce3d77088c 309d283a0	no	8
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	WenzelMigraine.pdf	89172 fe393cda0a23a2d124d81d61559996 39a244c	no	11
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	WiltonTegretol.pdf	234187 c0704daceea89de778a9b107727ae52b 6ebba4b0	no	4
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	WoolfSystemic.pdf	618489 4349064c98a8441e5d8633257995a f29b4377e	no	14
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>					12718123

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.